Pluvicto
Lutetium Lu 177 Vipivotide Tetraxetan · Targeted Radiopharmaceutical / Radioligand Therapy
Indications & Uses
PSMA-positive Metastatic Castration-Resistant Prostate Cancer, Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs), and Pheochromocytoma.
Contraindications
Hypersensitivity to active ingredient or any formulation excipients.
Side Effects & Warnings
Myelosuppression, radiation exposure, dry mouth/xerostomia, renal toxicity, nausea, fatigue.
Drug & Dietary Interactions
Caution with strong CYP3A inhibitors or inducers; review concurrent medications.
For educational and informational purposes only. Do not alter medication doses or regimens without consulting your licensed oncology physician or care team.
Ask About This Medication
Connect with an ONC-ORG counselor regarding drug access, copay relief, patient assistance programs, or related clinical trials.